Digital scoring of EpCAM and slug expression as prognostic markers in head and neck squamous cell carcinomas.


Journal

Molecular oncology
ISSN: 1878-0261
Titre abrégé: Mol Oncol
Pays: United States
ID NLM: 101308230

Informations de publication

Date de publication:
04 2021
Historique:
revised: 11 11 2020
received: 29 07 2020
accepted: 15 12 2020
pubmed: 20 12 2020
medline: 15 1 2022
entrez: 19 12 2020
Statut: ppublish

Résumé

Head and neck squamous cell carcinomas (HNSCCs) have poor clinical outcome owing to therapy resistance and frequent recurrences that are among others attributable to tumor cells in partial epithelial-to-mesenchymal transition (pEMT). We compared side-by-side software-based and visual quantification of immunohistochemistry (IHC) staining of epithelial marker EpCAM and EMT regulator Slug in n = 102 primary HNSCC to assess optimal analysis protocols. IHC scores incorporated expression levels and percentages of positive cells. Digital and visual evaluation of membrane-associated EpCAM yielded correlating scorings, whereas visual evaluation of nuclear Slug resulted in significantly higher overall scores. Multivariable Cox proportional hazard analysis defined the median EpCAM expression levels resulting from visual quantification as an independent prognostic factor of overall survival. Slug expression levels resulting from digital quantification were an independent prognostic factor of recurrence-free survival, locoregional recurrence-free survival, and disease-specific survival. Hence, we propose to use visual assessment for the membrane-associated EpCAM protein, whereas nuclear protein Slug assessment was more accurate following digital measurement.

Identifiants

pubmed: 33340247
doi: 10.1002/1878-0261.12886
pmc: PMC8024715
doi:

Substances chimiques

Biomarkers, Tumor 0
EPCAM protein, human 0
Epithelial Cell Adhesion Molecule 0
SNAI1 protein, human 0
Snail Family Transcription Factors 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1040-1053

Informations de copyright

© 2020 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.

Références

J Clin Oncol. 2013 Nov 1;31(31):3997-4013
pubmed: 24101045
Cancer Res. 2014 Jul 15;74(14):3695-706
pubmed: 24830722
Nat Rev Cancer. 2011 Jan;11(1):9-22
pubmed: 21160525
J Proteome Res. 2011 Aug 5;10(8):3429-38
pubmed: 21574648
Cancer Metastasis Rev. 2020 Sep;39(3):969-987
pubmed: 32507912
J Biol Chem. 2015 Oct 2;290(40):24574-91
pubmed: 26292218
Arch Pathol Lab Med. 2017 Sep;141(9):1267-1275
pubmed: 28557614
Diagn Pathol. 2011 Sep 23;6:87
pubmed: 21943197
PLoS One. 2010 Nov 30;5(11):e14130
pubmed: 21152431
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Nat Cell Biol. 2009 Feb;11(2):162-71
pubmed: 19136966
Oncogene. 2015 Jul 23;34(30):3917-25
pubmed: 25284583
J Cell Sci. 2003 Feb 1;116(Pt 3):499-511
pubmed: 12508111
Sci Rep. 2018 Oct 1;8(1):14582
pubmed: 30275505
Oral Oncol. 2013 Nov;49(11):1043-50
pubmed: 24035721
Gynecol Oncol. 2006 Nov;103(2):483-8
pubmed: 16678891
PLoS One. 2013;8(2):e56823
pubmed: 23451093
Cancer Cell. 2004 May;5(5):489-500
pubmed: 15144956
Nature. 2015 Jan 29;517(7536):576-82
pubmed: 25631445
Mol Oncol. 2018 Dec;12(12):2085-2101
pubmed: 30259648
Cell. 2017 Feb 9;168(4):670-691
pubmed: 28187288
PLoS Biol. 2018 Sep 27;16(9):e2006624
pubmed: 30261040
Science. 2011 Aug 26;333(6046):1157-60
pubmed: 21798893
BMC Cancer. 2010 Jun 25;10:331
pubmed: 20579375
J Biol Chem. 2019 Mar 1;294(9):3051-3064
pubmed: 30598504
Oral Oncol. 2019 Dec;99:104458
pubmed: 31704557
Cancer. 2013 Aug 15;119(16):3034-42
pubmed: 23696076
Nat Rev Mol Cell Biol. 2002 Mar;3(3):155-66
pubmed: 11994736
Cancer Res. 2015 Feb 1;75(3):480-6
pubmed: 25589349
Nat Rev Cancer. 2018 May;18(5):269-282
pubmed: 29497144
Histochem Cell Biol. 2015 Jan;143(1):1-9
pubmed: 25156293
Nat Rev Cancer. 2018 Feb;18(2):128-134
pubmed: 29326430
Clin Cancer Res. 2020 Jul 15;26(14):3616-3628
pubmed: 32161122
Clin Cancer Res. 2019 Mar 1;25(5):1505-1516
pubmed: 30171046
Radiat Oncol. 2018 Jul 3;13(1):123
pubmed: 29970111
Trends Cell Biol. 2015 Nov;25(11):675-686
pubmed: 26437589
Virchows Arch. 2016 Feb;468(2):191-8
pubmed: 26493985
Cell. 2017 Dec 14;171(7):1611-1624.e24
pubmed: 29198524
Pathol Res Pract. 2018 Dec;214(12):2087-2092
pubmed: 30377025
PLoS One. 2008;3(10):e3360
pubmed: 18852874

Auteurs

Henrik Schinke (H)

Department of Otorhinolaryngology, Head and Neck Surgery, Ludwig-Maximilians-University Munich, Germany.

Theresa Heider (T)

Research Unit Radiation Cytogenetics, Helmholtz Zentrum München, Neuherberg, Germany.

Timm Herkommer (T)

Research Unit Radiation Cytogenetics, Helmholtz Zentrum München, Neuherberg, Germany.

Florian Simon (F)

Department of Otorhinolaryngology, Head and Neck Surgery, Ludwig-Maximilians-University Munich, Germany.

Alexandra Blancke Soares (A)

Department of Otorhinolaryngology, Head and Neck Surgery, Ludwig-Maximilians-University Munich, Germany.

Gisela Kranz (G)

Department of Otorhinolaryngology, Head and Neck Surgery, Ludwig-Maximilians-University Munich, Germany.

Daniel Samaga (D)

Research Unit Radiation Cytogenetics, Helmholtz Zentrum München, Neuherberg, Germany.

Laura Dajka (L)

Research Unit Radiation Cytogenetics, Helmholtz Zentrum München, Neuherberg, Germany.

Annette Feuchtinger (A)

Research Unit Analytical Pathology, Helmholtz Zentrum München, Neuherberg, Germany.

Axel Walch (A)

Research Unit Analytical Pathology, Helmholtz Zentrum München, Neuherberg, Germany.

Laura Valeanu (L)

Institute of Pathology, Faculty of Medicine, LMU Munich, Germany.

Christoph Walz (C)

Institute of Pathology, Faculty of Medicine, LMU Munich, Germany.

Thomas Kirchner (T)

Institute of Pathology, Faculty of Medicine, LMU Munich, Germany.

Martin Canis (M)

Department of Otorhinolaryngology, Head and Neck Surgery, Ludwig-Maximilians-University Munich, Germany.

Philipp Baumeister (P)

Department of Otorhinolaryngology, Head and Neck Surgery, Ludwig-Maximilians-University Munich, Germany.
Clinical Cooperation Group "Personalized Radiotherapy in Head and Neck Cancer", Helmholtz Zentrum München, Neuherberg, Germany.

Claus Belka (C)

Clinical Cooperation Group "Personalized Radiotherapy in Head and Neck Cancer", Helmholtz Zentrum München, Neuherberg, Germany.
Department of Radiation Oncology, Ludwig-Maximilians-University Munich, Germany.

Cornelius Maihöfer (C)

Clinical Cooperation Group "Personalized Radiotherapy in Head and Neck Cancer", Helmholtz Zentrum München, Neuherberg, Germany.
Department of Radiation Oncology, Ludwig-Maximilians-University Munich, Germany.

Sebastian Marschner (S)

Clinical Cooperation Group "Personalized Radiotherapy in Head and Neck Cancer", Helmholtz Zentrum München, Neuherberg, Germany.
Department of Radiation Oncology, Ludwig-Maximilians-University Munich, Germany.

Ulrike Pflugradt (U)

Clinical Cooperation Group "Personalized Radiotherapy in Head and Neck Cancer", Helmholtz Zentrum München, Neuherberg, Germany.
Department of Radiation Oncology, Ludwig-Maximilians-University Munich, Germany.

Ute Ganswindt (U)

Department of Therapeutic Radiology and Oncology, Medical University of Innsbruck, Austria.

Julia Hess (J)

Research Unit Radiation Cytogenetics, Helmholtz Zentrum München, Neuherberg, Germany.
Clinical Cooperation Group "Personalized Radiotherapy in Head and Neck Cancer", Helmholtz Zentrum München, Neuherberg, Germany.

Horst Zitzelsberger (H)

Research Unit Radiation Cytogenetics, Helmholtz Zentrum München, Neuherberg, Germany.
Clinical Cooperation Group "Personalized Radiotherapy in Head and Neck Cancer", Helmholtz Zentrum München, Neuherberg, Germany.

Olivier Gires (O)

Department of Otorhinolaryngology, Head and Neck Surgery, Ludwig-Maximilians-University Munich, Germany.
Clinical Cooperation Group "Personalized Radiotherapy in Head and Neck Cancer", Helmholtz Zentrum München, Neuherberg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH